# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Ramsay Health Care Limited |
| Establishment Date | June 30, 1964 |
| Headquarters Location | Sydney, Australia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | Ramsay Health Care is advancing a multi-year digital and data transformation program, including the Ramsay Health Hub digital front door platform with 82% patient adoption and high satisfaction, a Patient Tracking system providing real-time notifications, and the Ramsay Data Hub for secure, data-driven decision making. The Group has implemented over 2,500 automations processing more than eight million transactions, and has digitised medical records across its operations. Innovation efforts also include investment in clinical trials, health research projects, and preventative healthcare start-ups, supported by five global Communities of Practice and leadership development programs. | Ramsay Health Care advanced its digital and operational transformation programs globally, with a focus on Australia, led by Group Chief Digital & Data Officer Dr Rachna Gandhi. Key initiatives include the Ramsay Australia Health Hub, a digital front door platform; a national mental health digital intake system; the Ramsay Australia Data Hub enabling AI and machine learning applications; development of a fit-for-purpose Electronic Health Record; and cybersecurity enhancements such as digital identity for doctors. Ramsay Santé's Living Labs serve as innovation incubators across France and Nordic countries, facilitating scalable healthcare innovations and AI deployment in clinical settings, including mammography screening AI algorithms at Capio Sankt Göran's Hospital. |
| Product Advantages | Ramsay offers a diversified healthcare portfolio across Australia, the UK, and Europe, with expanded services in mental health, day surgeries, orthopaedics, cancer, and cardiology. The Group operates a strategically located network of facilities with investments in physical and digital infrastructure, including new theatres, day unit capacity, and diagnostic units such as CT and MRI. Its portfolio supports integrated patient-centred care and includes public and private patient services, with a focus on delivering high-quality clinical outcomes and patient experience. | Ramsay Health Care offers a broad portfolio of healthcare services across multiple regions, including acute hospital care, mental health services (notably through Elysium Healthcare), primary care clinics, diagnostics and imaging services, and pharmacy e-commerce platforms. The Group expanded its service footprint with new facilities in Australia, the UK, and France, and developed out-of-hospital services such as Ramsay Psychology Clinics in Australia and primary care clinics in France. The Ramsay Clinical Trials Network supports over 250 clinical trials across Australia, enhancing research capabilities and treatment options. |
| Brand Recognition | Ramsay Health Care maintains strong long-term relationships with clinicians and payors, supported by regular engagement, education forums, and collaborative research initiatives. The Group consistently achieves high Net Promoter Scores across all regions, reflecting patient satisfaction and loyalty. It is recognised as a leading healthcare employer with gender diversity targets met in leadership, and has established a culture of innovation and care through programs such as the Ramsay Way Awards and global leadership academies. | Ramsay Health Care is recognized as a leading global healthcare provider with a strong culture embodied in 'The Ramsay Way.' The Group is acknowledged as a Top 10 most attractive employer in Australia and has received the Parenthood Trophy by the Observatory of Quality of Life at Work for Ramsay Santé. Capio is ranked as an 'ideal employer' by nurses in Sweden. The Group maintains long-term relationships with clinicians and governments, supported by comprehensive clinical governance frameworks and ongoing engagement. Employee recognition programs such as The Ramsay Way Awards and Quality Improvement Reward & Recognition Program reinforce its employer brand. |
| Reputation Ratings | Ramsay is committed to sustainability through its Ramsay Cares strategy aligned with the United Nations Sustainable Development Goals and has set science-based targets for greenhouse gas emissions reduction, including a net zero commitment by 2040. The Group integrates sustainability targets into executive incentives and financing arrangements, with 78% of funding linked to sustainability goals. It operates under a Global Responsible Sourcing Policy, assessing 60% of suppliers by spend for sustainability compliance, and maintains a Global Cybersecurity Framework externally validated and routinely tested. All regions maintain 100% hospital accreditation and meet quality and safety metrics. | Ramsay Health Care demonstrates commitment to sustainability through its Ramsay Cares Sustainability Strategy, which includes science-based decarbonisation targets aligned with a 1.5-degree pathway and adherence to Task Force on Climate-related Financial Disclosures (TCFD) recommendations. The Group achieved 40% supplier assessment by EcoVadis in FY23 and implemented a Global Responsible Sourcing Policy aligned with UN Guiding Principles on Business and Human Rights and International Labour Organisation standards. Ramsay maintains a Global Cybersecurity Framework validated externally and complies with environmental regulations without known breaches. The Group's hospitals maintain 100% accreditation across all regions and meet key quality and safety performance indicators. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | People caring for people |
| Vision Statement | To be a leading healthcare provider of the future |
| Core Values | N/A |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 16,660.2 | 14,963.9 | 13,312.4 | Millions | AUD |
| Cost of Goods Sold | (15,966.4) | (13,827.7) | N/A | Millions | AUD |
| Gross Profit | N/A | N/A | N/A | Millions | AUD |
| Operating Expense | N/A | N/A | N/A | Millions | AUD |
| Operating Income | 997.6 | 1,001.4 | N/A | Millions | AUD |
| Net Profit | 881.4 | 365.5 | 379.2 | Millions | AUD |
| Income before income taxes | 384.6 | 527.1 | 523.2 | Millions | AUD |
| Income tax expense(benefit) | (121.3) | (181.5) | (159.3) | Millions | AUD |
| Interest Expense | (620.0) | (514.2) | N/A | Millions | AUD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 20,894.0 | 21,030.2 | 19,514.5 | Millions | AUD |
| Current Assets | 3,872.8 | 3,895.8 | 3,285.5 | Millions | AUD |
| Non-Current Assets | 17,021.2 | 17,134.4 | 16,229.0 | Millions | AUD |
| Total Liabilities | 15,366.5 | 16,207.0 | 14,988.3 | Millions | AUD |
| Current Liabilities | 4,180.3 | 3,810.4 | 3,747.6 | Millions | AUD |
| Non-Current Liabilities | 11,186.2 | 12,396.6 | 11,240.7 | Millions | AUD |
| Shareholders' Equity | 5,527.5 | 4,823.2 | 4,526.2 | Millions | AUD |
| Retained Earnings | 2,500.2 | 1,786.7 | 1,708.7 | Millions | AUD |
| Total Equity and Liabilities | 20,894.0 | 21,030.2 | 19,514.5 | Millions | AUD |
| Inventories | 379.4 | 388.6 | 376.8 | Millions | AUD |
| Prepaid Expenses | 244.6 | 202.3 | 197.1 | Millions | AUD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 1,292.8 | 1,279.6 | 715.5 | Millions | USD |
| Net Cash Flow from Investing | 159.7 | (713.8) | (730.7) | Millions | USD |
| Net Cash Flow from Financing | (1,450.1) | (242.4) | (239.2) | Millions | USD |
| Net Increase/Decrease in Cash | 2.4 | 323.4 | (732.2) | Millions | USD |
| Dividends | (158.3) | (236.8) | (351.9) | Millions | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 195.84% | 192.41% | N/A | Millions | AUD |
| Operating Margin | 5.99% | 6.69% | N/A | Millions | AUD |
| Net Profit Margin | 5.29% | 2.44% | 2.85% | Millions | AUD |
| Current Ratio | 92.64% | 102.24% | 87.67% | Millions | AUD |
| Quick Ratio | 77.72% | 86.73% | 72.36% | Millions | AUD |
| Interest Coverage | 160.90% | 194.75% | N/A | Millions | AUD |
| Asset Turnover | 79.48% | 73.81% | N/A | Millions | AUD |
| Debt-to-Equity | 278.00% | 336.02% | 331.15% | Millions | AUD |
| Return on Equity | 17.03% | 7.82% | N/A | Millions | AUD |
| Return on Assets | 4.20% | 1.80% | N/A | Millions | AUD |
| Effective Tax Rate | 31.54% | 34.43% | 30.45% | Millions | AUD |
| Dividend Payout Ratio | 17.96% | 64.79% | 92.80% | Millions | AUD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Revenue from contracts with customers: £16,660.2m | Revenue from contracts with customers: £14,963.9m | N/A |
| Revenue by Geographic Region | Australia: £6,061.6m, UK: £2,360.8m, France: £5,764.2m, Nordics: £2,593.6m | Australia: £5,711.0m, UK: £1,941.2m, France: £5,291.2m, Nordics: £2,395.7m | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue has shown a consistent growth trend from 2022 to 2024, increasing from £13,312.4m in 2022 to £14,963.9m in 2023, and further to £16,660.2m in 2024, representing a growth of approximately 12.4% from 2022 to 2023 and 11.4% from 2023 to 2024. The gross margin has improved slightly, with a gross margin of 195.84% in 2024 compared to 192.41% in 2023. Revenue from contracts with customers has been the sole contributor to revenue, indicating a focused business model. Geographically, revenue distribution has shifted with Australia leading at £6,061.6m in 2024, followed by France at £5,764.2m, UK at £2,360.8m, and Nordics at £2,593.6m, showing growth in all regions, particularly Australia which increased from £5,711.0m in 2023. |
| Operating Efficiency | Operating margin has shown a slight decline from 6.69% in 2023 to 5.99% in 2024, indicating a decrease in operating efficiency despite an increase in revenue. Operating income has remained relatively stable, with £1,001.4m in 2023 and £997.6m in 2024, suggesting that while revenue has increased, the cost structure may not have improved proportionately. The operating income as a percentage of revenue reflects a need for better cost management strategies to enhance profitability. |
| External & One-Off Impact | The effective tax rate has decreased from 34.43% in 2023 to 31.54% in 2024, which positively impacts net profit, increasing it to £881.4m in 2024 from £365.5m in 2023. However, the net profit margin has only slightly improved from 2.44% in 2023 to 5.29% in 2024, indicating that while tax efficiency has improved, other factors may be constraining overall profitability. There are no noted non-recurring items or unusual patterns in the data provided, suggesting a stable operational environment without significant external disruptions. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets decreased slightly to AUD 20,894.0 million from AUD 21,030.2 million in 2023, indicating a marginal decline in asset growth. However, total liabilities also decreased to AUD 15,366.5 million from AUD 16,207.0 million, reflecting improved liability management. Shareholders' equity increased significantly to AUD 5,527.5 million from AUD 4,823.2 million, showcasing a stronger equity position. The current ratio decreased to 92.64%, indicating a slight decline in liquidity, while the debt to equity ratio improved to 278.00%, suggesting a more favorable capital structure. | In 2023, the company reported total assets of AUD 21,030.2 million, an increase from AUD 19,514.5 million in 2022, indicating positive asset growth. Total liabilities rose to AUD 16,207.0 million from AUD 14,988.3 million, which may raise concerns about liability management. Shareholders' equity also improved to AUD 4,823.2 million from AUD 4,526.2 million, reflecting a strengthening equity position. The current ratio was at 102.24%, indicating good liquidity, while the debt to equity ratio was high at 336.02%, suggesting a leveraged capital structure. |
| Profitability and earnings quality | In 2024, the company achieved revenue of AUD 16,660.2 million, up from AUD 14,963.9 million in 2023, indicating strong revenue growth. The net profit increased significantly to AUD 881.4 million from AUD 365.5 million, resulting in a net profit margin of 5.29%, up from 2.44% in 2023. The return on equity (ROE) improved to 17.03% from 7.82%, indicating enhanced earnings quality and sustainability. Operating income remained relatively stable at AUD 997.6 million, reflecting consistent operational performance. | In 2023, the company reported revenue of AUD 14,963.9 million, an increase from AUD 13,312.4 million in 2022. The net profit was AUD 365.5 million, resulting in a net profit margin of 2.44%, which was an improvement from 2.85% in 2022. The return on equity (ROE) was 7.82%, indicating moderate profitability. Operating income was AUD 1,001.4 million, suggesting stable operational performance despite the challenges faced in the market. |
| Operational efficiency | In 2024, the operating margin decreased to 5.99% from 6.69% in 2023, indicating a slight decline in operational efficiency. The asset turnover ratio improved to 79.48%, up from 73.81% in 2023, suggesting better asset utilization. Net cash from operations increased to AUD 1,292.8 million from AUD 1,279.6 million, indicating effective cash flow management. However, the overall decrease in operating margin may require attention to cost management strategies. | In 2023, the operating margin was 6.69%, reflecting strong operational efficiency. The asset turnover ratio was 73.81%, indicating effective utilization of assets. Net cash from operations was AUD 1,279.6 million, which was an increase from AUD 715.5 million in 2022, showcasing improved cash flow management. The company maintained a stable operational performance, although the operating margin suggests potential areas for cost optimization. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved to 278.00%, down from 336.02% in 2023, indicating better debt management. The interest coverage ratio decreased to 160.90% from 194.75%, which may signal increased financial risk due to higher interest expenses. The current ratio of 92.64% suggests potential liquidity concerns, while the effective tax rate decreased to 31.54%, which may provide some relief in tax obligations. Overall, while there are improvements in leverage, the company should monitor liquidity closely. | In 2023, the debt to equity ratio was high at 336.02%, indicating significant leverage and potential financial risk. The interest coverage ratio was 194.75%, suggesting that the company was able to cover its interest expenses comfortably. The current ratio of 102.24% indicated good liquidity, while the effective tax rate was 34.43%, which could impact net profitability. The company faced risks related to high leverage, but maintained a manageable interest coverage. |
| Future financial performance projection | Based on the 2024 data, the company is positioned for continued growth, with revenue increasing significantly. The improvement in net profit and return on equity suggests a sustainable earnings trajectory. Investment activities appear to be stabilizing, with net cash from investing showing a positive trend. The company may focus on market expansion, particularly in regions like Australia and France, to leverage its revenue growth. However, attention to liquidity and operational efficiency will be crucial for maintaining financial health. | In 2023, the company demonstrated a positive trajectory with revenue growth and improved profitability metrics. The focus on operational efficiency and cash flow management is expected to support future performance. However, the high debt to equity ratio indicates that the company may need to consider strategies for reducing leverage. Future projections should include plans for market expansion and investment in growth opportunities to sustain the upward trend in financial performance. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | Ramsay Health Care primarily operates a healthcare services business model, generating revenue through providing health care services to both public and private patients. The company derives income from contracts with customers, which includes revenue from patients, ancillary services, and government grants. In FY24, revenue from contracts with customers was A$16,660.2 million, reflecting a growth of 11.3% compared to the previous year. | The company primarily operates in the healthcare sector, generating revenue by providing health care and related services to both public and private patients in the community. Its revenue streams include income from patients, government contracts, rental revenue, and ancillary services. In 2023, the revenue from patients was $14,379.6 million, and total revenue from contracts with customers was $14,963.9 million. |
| Market Position | Ramsay Health Care is positioned as a market leader in the healthcare sector, with a strong presence in Australia, the UK, France, and the Nordics. The company reported total segment revenue of A$16,780.2 million in FY24, with significant contributions from Australia (A$6,061.6 million) and the UK (A$2,360.8 million). Ramsay is focused on leveraging its extensive network of facilities and strategic relationships to capitalize on long-term growth opportunities in the healthcare market. | The company is positioned as a market leader in the healthcare sector, with significant operations across multiple regions including Asia Pacific, the UK, France, and the Nordics. It has reported total segment revenue of $15,339.1 million in 2023, reflecting an 11.6% growth compared to the previous year. The company is focused on expanding its services and improving operational efficiency to maintain its competitive edge. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | Ramsay faces market risks related to interest rate fluctuations and foreign exchange rates, which could impact financial performance. The Group actively manages these risks through derivative transactions, including interest rate swaps and foreign exchange contracts. | Ramsay faces market risks including fluctuations in demand due to changing patient and doctor expectations, increased competition from digitally-enabled lower-cost providers, and economic factors affecting private health insurance coverage. The company is also impacted by government funding changes and the rising costs associated with healthcare services. |
| Operational Risks | Operational risks include reliance on international supply chains, which may be affected by geopolitical tensions and economic conditions, potentially impacting healthcare provision. Ramsay is addressing these risks through supplier relationship management and alternate supply arrangements. | Operational risks include reliance on international supply chains, which may be affected by geopolitical tensions, inflation, and severe weather events. Additionally, workforce shortages, particularly in nursing and clinical roles, pose a significant challenge to maintaining service delivery and operational efficiency. |
| Financial Risks | The Group is exposed to financial risks such as interest rate, foreign currency, credit, and liquidity risks. To mitigate these, Ramsay employs a financial risk management policy that includes the use of derivatives and regular monitoring of exposure levels. | The Group is exposed to financial risks such as interest rate, foreign currency, credit, and liquidity risks. To mitigate these, Ramsay employs a financial risk management policy that includes the use of derivatives like interest rate swaps and foreign exchange contracts, and maintains relationships with high credit quality financial institutions to manage credit risk. |
| Compliance Risks | Ramsay operates in a highly regulated industry, facing compliance risks related to legal and regulatory obligations. The Group has established a framework to manage these risks, including employee training and effective management of licensing and accreditation. | Ramsay operates in a highly regulated industry, facing compliance risks related to extensive laws and regulations governing healthcare. The company has established a framework to manage legal and regulatory obligations, ensuring adherence to licensing requirements and minimizing the risk of litigation. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Craig McNally | MD & CEO | £4,208,002,000 |
| Martyn Roberts | Group CFO | £1,712,059,000 |
| David Thodey | Chair | £502,513,000 |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | Climate-related risks are identified, assessed and managed at a Group level, with input from project- and regional-level stakeholders. A comprehensive, high-level risk assessment was conducted in FY21 to evaluate climate-related risks and opportunities, identifying key common risk areas and their potential implications for strategic and operational aspects of the Group. In FY24, the risk and opportunity assessment was refreshed to reflect any material changes to the business and external environment. | Climate change risks are managed within the Group's risk management framework. A high-level risk and opportunity assessment identified a range of physical risks. The materiality assessment is informed by the Sustainability Accounting Standards Board Materiality Map and reviewed annually by the Global Sustainability Committee. |
| Control activities | Ramsay has in place a comprehensive Clinical Governance Framework, which includes clinical effectiveness to ensure a high standard of quality and continuous improvement, clinical risk management ensuring services are safe and minimize risk of error, and tracking quality through measures such as clinical incidents and patient experience. Additionally, Ramsay maintains modern governance policies and practices to operate with integrity and meet regulatory requirements. | The Group has implemented a comprehensive Clinical Governance Framework, which includes clinical effectiveness, clinical risk management, credentialing, licensing, and training frameworks. The Board approved a new Global Code of Conduct and a Global Responsible Sourcing Policy, which sets expectations for suppliers regarding environmental and resource sustainability. |
| Monitoring mechanisms | The Global Risk Management Committee oversees financial and non-financial risks including sustainability and any material social and environmental risks, climate risks and opportunities. The Board is updated at least annually on sustainability, including climate-related issues, and has committees that monitor various aspects of risk management. | The Global Risk Management Committee oversees sustainability and material social and environmental risks. The Audit Committee reviews sustainability issues related to financial matters and approved an Internal Audit Plan that includes assurance activities related to the net zero plan. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | The Board is determined to uphold the highest standards of corporate governance and nurture the culture and principles of The Ramsay Way throughout the business. The effectiveness of the internal control system is assessed through continuous review processes, including updates to Board and Committee Charters and policies. | The Board and Management regularly review corporate governance policies and processes to ensure they meet governance standards and regulatory requirements. The effectiveness of the internal control system is assessed through various committees, including the Audit Committee and the Risk Management Committee. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | In FY24, Ramsay Health Care acquired certain businesses in Australia and Europe within the healthcare sector, with a total cash outflow of $13.1 million for these business combinations. The fair value of identifiable net assets was $4.3 million, with goodwill arising from these acquisitions amounting to $14.7 million. | Ramsay's growth has been driven by acquisitions within the healthcare sector. In FY23, Ramsay Elysium Holdings Limited acquired two UK-based child and adolescent mental health services facilities from Regis Healthcare Ltd for $68.1 million (£40 million). Additionally, Ramsay Santé is exploring the sale of Ramsay Sime Darby (RSD) in partnership with Sime Darby Berhad, with a process underway to receive non-binding indicative offers. |
| New technologies | Ramsay is investing in digital transformation initiatives, including the Ramsay Health Hub, which provides a single online access point for patients, doctors, and teams. The platform has achieved 82% patient adoption. Additionally, the company is focused on enhancing its digital capabilities through a multi-year transformation strategy aimed at creating a digitally-enabled healthcare ecosystem. | Ramsay is focused on a major digital and data transformation strategy aimed at creating a digitally-enabled healthcare ecosystem. Key initiatives include the Ramsay Australia Health Hub, which aims to establish a single digital front door for patients, and a national mental health digital intake system being rolled out across 20+ clinics. The company is also investing in AI tools for clinicians to enhance patient care and has launched Living Labs to prioritize and test scalable innovations. |
| Organisational Restructuring | Ramsay is committed to developing its workforce through various initiatives, including apprenticeships, graduate pathways, and leadership development programs. The Global Leadership Academy saw a 39% increase in participants in FY24, with nearly 300 leaders participating in Ramsay Australia's new leadership academy program. The company is also focused on improving employee engagement and retention. | Ramsay has implemented various workforce initiatives to address skill shortages and improve employee engagement. Key priorities include providing flexible working conditions, expanding leadership programs, and investing in technology to simplify processes. The company has also launched new training programs and professional development pathways, including a centralised People Centre for onboarding new hires and a Global Graduate Programme for emerging leaders. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | Ramsay's cost base is subject to various levels of wage, supply cost, and energy price inflation, as well as changes to interest rates on its debt. Material changes in inflation and interest rates could significantly impact financial performance, leading to limited growth or inability to maintain earnings, difficulty in attracting and retaining employees, and increased costs due to high inflation and interest rates. Additionally, geopolitical tensions and international sanctions may affect supply availability, while government policies could impact the affordability of private health insurance, particularly in Australia. | Ramsay faces significant economic challenges including inflationary pressures that are increasing costs across various sectors, particularly in labor and supply chains. Geopolitical tensions and international sanctions may disrupt supply availability, impacting healthcare provision. Additionally, changes in government funding and health insurance policies could materially affect operations, especially in Australia, where affordability of private health insurance is a concern. The potential for rising unemployment and economic downturns could lead to declines in private health insurance membership, further straining financial performance. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | Ramsay faces competitive pressures from both established industry players and new entrants, particularly in the context of innovation and disruption within the healthcare sector. The company must navigate challenges related to the actions of competitors, the need for continuous clinical innovation, and the ability to identify future acquisitions. Additionally, the entry of digitally-enabled, lower-cost competitors poses a significant threat to Ramsay's market position, necessitating ongoing adaptation and strategic responses to maintain competitiveness. | Ramsay is experiencing competitive pressures from both established players and new entrants in the healthcare market. The emergence of digitally-enabled, lower-cost competitors is reshaping the competitive landscape. Additionally, Ramsay's growth strategy may be hindered by industry disruptions and the actions of competitors, which could limit its ability to maintain earnings and attract talent. The company must navigate these competitive dynamics while also investing in innovation and operational excellence to enhance its market position. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | In FY24, Ramsay Health Care invested $286 million in R&D and innovation initiatives, focusing on expanding treatment capacity and enhancing digital capabilities. The Ramsay Hospital Research Foundation (RHRF) awarded $25 million for 53 projects in key therapeutic areas, including a notable $400,000 for the DARO-Lipid study on prostate cancer. The company is also advancing its digital transformation with initiatives like the Ramsay Health Hub and Patient Tracking system, aimed at improving patient experiences and operational efficiency. | Ramsay Health Care Limited invested significantly in R&D and innovation in 2023, with a total of $5 million allocated to the Ramsay Hospital Research Foundation (RHRF) for various health and medical research initiatives. The RHRF funded six new research grants and increased clinical trials by 11%, now totaling over 250 trials across Australia. Notably, a groundbreaking trial for a personalized cancer vaccine therapy targeting melanoma patients was initiated. Additionally, Ramsay's digital and data investment reached $108 million, focusing on enhancing digital capabilities, including the development of a digital front door for patients and a fit-for-purpose Electronic Health Record set to roll out in 2024. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | Ramsay Health Care launched several new facilities in FY24, including the $145 million Northern Private Hospital in Melbourne, which features advanced technology and sustainable design principles. Additionally, the Glendon Wood Hospital in the UK and the Emerald Place Clinic for mental health in Surrey were opened, enhancing service offerings. These new facilities are part of Ramsay's strategy to integrate primary care with hospital services, thereby improving patient access and care quality. | In 2023, Ramsay Health Care launched several innovative products and services, including the Ramsay Santé's Living Labs, which serve as incubators for scalable healthcare innovations. These labs focus on improving surgical pathways and developing efficient documentation methods. Furthermore, Ramsay Santé introduced an online health and wellbeing marketplace, offering over 50,000 healthcare products, and launched a new pharmacy e-commerce site. These initiatives reflect Ramsay's commitment to enhancing patient care and experience through technology and innovative service delivery. |
